Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: In silico evaluation of currently recommended doses

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1339-1349

  Zvada, Simbarashe P ^a   Denti, Paolo ^a   Donald, Peter R ^b   Schaaf, H Simon ^b   Thee, Stephanie ^b,c   Seddon, James A ^b,d   Seifart, Heiner I ^e   Smith, Peter J ^a   McIlleron, Helen M ^a   Simonsson, Ulrika S H ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anti Mycobacterium; Modelling and simulation; NONMEM; Paediatrics; Pharmacometrics

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; NEWBORN; PLASMA CONCENTRATION-TIME CURVE; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCHOOL CHILD; RECOMMENDED DRUG DOSE; STEADY STATE; TUBERCULOSIS; INFORMATION PROCESSING; SOUTH AFRICA; STATISTICAL MODEL;

ANTITUBERCULAR AGENTS; AUTOMATIC DATA PROCESSING; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; ISONIAZID; MALE; MODELS, STATISTICAL; PYRAZINAMIDE; RIFAMPIN; SOUTH AFRICA; TUBERCULOSIS;

EID: 84898418716     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt524     Document Type: Article

References (44)

1. WHO. Global Tuberculosis Report 2013. Geneva: WHO. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng. pdf (31 December 2013, date last accessed).
2. Marais BJ, Hesseling AC, Gie RP et al. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis 2006; 10: 259-63.
3. Hu Y, Coates AR, Mitchison DA. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2006; 10: 317-22.
4. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988; 94: 845-50.
5. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
6. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
7. McIlleron H, Willemse M, Werely CJ et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis 2009; 48: 1547-53.
8. Schaaf HS, Willemse M, Cilliers K et al. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 2009; 7: 19.
9. Schaaf HS, Parkin DP, Seifart HI et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005; 90: 614-8.
10. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67.
11. Gurumurthy P, Ramachandran G, Hemanth Kumar AK et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473-5.
12. WHO. Rapid Advice: Treatment of Tuberculosis in Children. Geneva: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241500449_eng. pdf (14 September 2011, date last accessed).
13. WHO. Annual Meeting of the Childhood TB Subgroup, Kuala Lumpur, 11 November 2012: Meeting Report. Geneva: WHO, Stop TB Partnership, 2012. http://www.stoptb.org/wg/dots_expansion/childhoodtb/assets/ documents/Report%20Child%20TB%20Subgroup%20Meeting%2011% 20Nov%202012%20final.pdf (18 February 2013, date last accessed).
14. McIlleron H, Willemse M, Schaaf HS et al. Pyrazinamide plasma concentrations in young children with tuberculosis. Pediatr Infect Dis J 2011; 30: 262-5.
15. Thee S, Seddon JA, Donald PR et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 2011; 55: 5560-7.
16. McIlleron H, Norman J, Kanyok TP et al. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J Antimicrob Chemother 2007; 60: 1398-401.
17. Beal S, Sheiner LB, Boeckmann A et al. NONMEM User's Guides (1989-2009). Ellicott City, MD: Icon Development Solutions, 2009.
18. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735-50.
19. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
20. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32.
21. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
22. Engle WA. Age terminology during the perinatal period. Pediatrics 2004; 114: 1362-4.
23. Savic RM, Jonker DM, Kerbusch T et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-26.
24. Wilkins JJ, Savic RM, Karlsson MO et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008; 52: 2138-48.
25. Chigutsa E, Visser ME, Swart EC et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011; 55: 4122-7.
26. Heymsfield SB, Olafson RP, Kutner MH et al. A radiographic method of quantifying protein-calorie undernutrition. Am J Clin Nutr 1979; 32: 693-702.
27. Gibson R. Anthropometric assessment of body size. In: Principles of Nutritional Assessment, Second Edition. New York: Oxford University Press, 2005; 255-6.
28. Holford N. The visual predictive check-superiority to standard diagnostic (Rorschach) plots. In: Abstracts of the Fourteenth Population Approach Group in Europe Meeting, Pamplona, 2005. Abstract 738. http://www.page-meeting.org/?abstract=738 (10 January 2014, date last accessed).
29. Wilkins JJ, Langdon G, McIlleron H et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 2011; 72: 51-62.
30. Wilkins JJ, Langdon G, McIlleron H et al. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62: 727-35.
31. WHO. National Tuberculosis Management Guidelines 2008. Geneva: WHO. http://www.who.int/hiv/pub/guidelines/south_africa_tb.pdf (10 February 2013, date last accessed).
32. Pariente-Khayat A, Rey E, Gendrel D et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther 1997; 62: 377-83.
33. Zhu R, Kiser JJ, Seifart HI et al. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 2012; 52: 511-9.
34. Pargal A, Rani S. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int J Tuberc Lung Dis 2001; 5: 70-9.
35. Mitchison DA. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998; 2: 612-5.
36. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
37. Chideya S, Winston CA, Peloquin CA et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48: 1685-94.
38. Parkin DP, Vandenplas S, Botha FJ et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717-22.
39. Weiner M, Benator D, Burman W et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-91.
40. Agrawal S, Singh I, Kaur KJ et al. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol Res 2004; 50: 317-27.
41. McIlleron H, Wash P, Burger A et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-7.
42. Fuselli S, Gilman RH, Chanock SJ et al. Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J 2007; 7: 144-52.
43. Sabbagh A, Darlu P, Crouau-Roy B et al. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One 2011; 6: e18507.
44. Weiner M, Peloquin C, BurmanWet al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010; 54: 4192-200.